Elotuzumab is under clinical development by AbbVie and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to GlobalData, Phase II drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Elotuzumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Elotuzumab overview
Elotuzumab (HuLuc63/Empliciti) is a humanized anti-CS1 monoclonal IgG1 antibody acts as an antineoplastic agent. It is formulated as lyophilized powder for solution for intravenous route of administration. Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (Relapsed/Refractory) who have received one to three prior therapies, and also in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (Relapsed/Refractory) who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor and in combination with pomalidomide and dexamethasone is indicated for the treatment of patients with relapsed and refractory multiple myeloma.
The drug candidate was under development for the treatment of IgG4 related disease and is under development for multiple myeloma (first line), post-essential thrombocythemia myelofibrosis (Post-ET MF) and primary myelofibrosis.
AbbVie overview
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of Elotuzumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
